News

Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing

Texas is the first state to fund clinical trials of ibogaine, investing $50 million in public funds to explore its potential for treating PTSD, addiction, and TBI—with future revenues supporting veterans’ programs.

Texas governor signs bill allocating up to $100 million in funding for psychedelics research

Texas has passed a landmark bill dedicating up to $100 million—half from public funds—to study ibogaine for conditions like PTSD, TBI, and addiction. A portion of future revenue will directly support veterans’ programs, marking a major step toward expanding access to psychedelic-assisted therapies.

Los Angeles Times: California Veterans Fight to Fast-Track Study of ‘Lifesaving’ Psychedelic Therapy

Veterans Exploring Treatment Solutions (VETS) Takes Center Stage at Psychedelic Science 2025

Veterans Exploring Treatment Solutions (VETS) brought its mission to the forefront at Psychedelic Science 2025, spotlighting the urgent need for access, equity, and innovation in veteran mental health. From policy advocacy to powerful storytelling, VETS delivered a bold message: healing is a right—and veterans deserve the freedom to pursue it.

Advocate reacts to Texas governor signing psychedelic research bill into law

Texas has taken a historic step toward advancing psychedelic science and veteran mental health. With the signing of SB 2308, the state will invest $50 million into ibogaine research—opening the door for FDA-approved studies on a treatment veterans have long sought abroad. As VETS continues advocating for clinical access to promising therapies, this milestone positions Texas at the forefront of evidence-based innovation for PTSD, TBI, and addiction.